David O'Hagan

David is the CEO, inventor, and co-founder of Esperovax. Dr. O’Hagan Earned his Ph.D. in Molecular Medicine and Genetics developing microarray technology for Genomic Solutions - that he spun off as Streamline Proteomics with Sloan Ventures, using microspheres to capture and analyze genomic and proteomic data. He completed his post-doctoral work at the Burnham Institute (La Jolla, California), returning later to Michigan to develop a novel cancer therapy for melanoma at the Karmanos Cancer Institute. Dr. O’Hagan also developed several products as a product manager for Stratagene (La Jolla, California), followed by a position in sales for Sigma-Aldrich (St. Louis, Missouri).

Dr. O’Hagan earned his Ph.D. in Molecular Biology from Wayne State University School of Medicine in 2002. Prior to that, he gained his Bachelor of Science degree in Biophysics at Lawrence Technological University.